Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Sexual Health as Part of Gynecologic Cancer Care: What Do Patients Want?

Hay CM, Donovan HS, Hartnett EG, Carter J, Roberge MC, Campbell GB, Zuchelkowski BE, Taylor SE.

Int J Gynecol Cancer. 2018 Nov;28(9):1737-1742. doi: 10.1097/IGC.0000000000001376.

PMID:
30358703
2.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team.

PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.

3.

Super-Utilization of Health Care Resources Among Gynecologic Oncology Patients.

Hay CM, Kelley JL 3rd, Edwards RP, Pombier KM, Comerci JT Jr.

Am J Med Qual. 2018 Sep/Oct;33(5):509-513. doi: 10.1177/1062860618757343. Epub 2018 Feb 20.

PMID:
29463092
4.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

5.

Strategies for Introducing Outpatient Specialty Palliative Care in Gynecologic Oncology.

Hay CM, Lefkowits C, Crowley-Matoka M, Bakitas MA, Clark LH, Duska LR, Urban RR, Creasy SL, Schenker Y.

J Oncol Pract. 2017 Sep;13(9):e712-e720. doi: 10.1200/JOP.2017.020818. Epub 2017 Aug 1.

6.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.

PLoS One. 2017 Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017.

7.

Stopping conventional showering decreases Pseudomonas infections in left ventricular assist device patients.

Aburjania N, Sherazi S, Tchantchaleishvili V, Alexis JD, Hay CM.

Int J Artif Organs. 2017 Jun 9;40(6):282-285. doi: 10.5301/ijao.5000590. Epub 2017 Apr 18.

PMID:
28430297
8.

Gynecologic Oncologist Views Influencing Referral to Outpatient Specialty Palliative Care.

Hay CM, Lefkowits C, Crowley-Matoka M, Bakitas MA, Clark LH, Duska LR, Urban RR, Chen LM, Creasy SL, Schenker Y.

Int J Gynecol Cancer. 2017 Mar;27(3):588-596. doi: 10.1097/IGC.0000000000000893.

9.

Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important?

Hay CM, Courtney-Brooks M, Lefkowits C, Hagan TL, Edwards RP, Donovan HS.

Gynecol Oncol. 2016 Nov;143(2):367-370. doi: 10.1016/j.ygyno.2016.08.235. Epub 2016 Aug 13.

10.

Targeting CD73 in the tumor microenvironment with MEDI9447.

Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF.

Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug.

11.

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P.

PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016.

12.

Biomarkers p16, Human Papillomavirus and p53 Predict Recurrence and Survival in Early Stage Squamous Cell Carcinoma of the Vulva.

Hay CM, Lachance JA, Lucas FL, Smith KA, Jones MA.

J Low Genit Tract Dis. 2016 Jul;20(3):252-6. doi: 10.1097/LGT.0000000000000182.

PMID:
26855143
13.

Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.

Ragni MV, DiMichele DM, Hay CM, Malec LM, Seaman CD, Li J, Yabes JG, Butenas S, Brummel-Ziedins K.

Haemophilia. 2016 Mar;22(2):240-247. doi: 10.1111/hae.12830. Epub 2015 Oct 30.

PMID:
26517283
14.

Case records of the Massachusetts General Hospital. Case 23-2014. A 41-year-old man with fevers, rash, pancytopenia, and abnormal liver function.

Hay CM, Shepard JA, Hyle EP, Duncan LM.

N Engl J Med. 2014 Jul 24;371(4):358-66. doi: 10.1056/NEJMcpc1404140. No abstract available.

PMID:
25054720
15.

Adrenal insufficiency in a woman secondary to standard-dose inhaled fluticasone propionate therapy.

Hay CM, Spratt DI.

Endocrinol Diabetes Metab Case Rep. 2014;2014:130080. doi: 10.1530/EDM-13-0080. Epub 2014 Feb 1.

16.

Mechanisms regulating the development of oligodendrocytes and central nervous system myelin.

Mitew S, Hay CM, Peckham H, Xiao J, Koenning M, Emery B.

Neuroscience. 2014 Sep 12;276:29-47. doi: 10.1016/j.neuroscience.2013.11.029. Epub 2013 Nov 22. Review.

PMID:
24275321
17.

MYRF is a membrane-associated transcription factor that autoproteolytically cleaves to directly activate myelin genes.

Bujalka H, Koenning M, Jackson S, Perreau VM, Pope B, Hay CM, Mitew S, Hill AF, Lu QR, Wegner M, Srinivasan R, Svaren J, Willingham M, Barres BA, Emery B.

PLoS Biol. 2013;11(8):e1001625. doi: 10.1371/journal.pbio.1001625. Epub 2013 Aug 13.

18.

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB.

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050. Epub 2013 May 9.

19.

Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS.

Koenning M, Jackson S, Hay CM, Faux C, Kilpatrick TJ, Willingham M, Emery B.

J Neurosci. 2012 Sep 5;32(36):12528-42. doi: 10.1523/JNEUROSCI.1069-12.2012.

20.

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL.

PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3.

21.

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Gorse GJ, Newman MJ, deCamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2012 May;19(5):649-58. doi: 10.1128/CVI.00038-12. Epub 2012 Mar 7.

22.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.

Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23.

23.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.

24.

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.

Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M.

JAMA. 2007 Apr 11;297(14):1577-82.

PMID:
17426277
25.

Exogenous glycine partially attenuates homocysteine-induced apoptosis and membrane peroxidation in chick embryos.

Miller RR Jr, Hay CM, Striegnitz TR, Honsey LE, Coykendall CE, Blacquiere KD.

Comp Biochem Physiol C Toxicol Pharmacol. 2006 Sep;144(1):25-33. Epub 2006 May 26.

PMID:
16809069
26.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.

J Infect Dis. 2006 May 1;193(9):1223-8. Epub 2006 Mar 28.

PMID:
16586358
27.

Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ.

J Antimicrob Chemother. 2004 Aug;54(2):566-9. Epub 2004 Jul 21.

PMID:
15269195
28.

Enhanced gene transfer to rabbit jugular veins by an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob.

Hay CM, De Leon H, Jafari JD, Jakubczak JL, Mech CA, Hallenbeck PL, Powell SK, Liau G, Stevenson SC.

J Vasc Res. 2001 Jul-Aug;38(4):315-23.

PMID:
11455202
29.

Persistence of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte clones in a subject with rapid disease progression.

Islam SA, Hay CM, Hartman KE, He S, Shea AK, Trocha AK, Dynan MJ, Reshamwala N, Buchbinder SP, Basgoz NO, Kalams SA.

J Virol. 2001 May;75(10):4907-11.

30.

Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.

Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, D'Aquila RT, Wolinsky SM, Crawford JM, Montefiori DC, Walker BD.

J Virol. 1999 Jul;73(7):5509-19.

31.

Immune control of HIV-1 replication.

Walker BD, Rosenberg ES, Hay CM, Basgoz N, Yang OO.

Adv Exp Med Biol. 1998;452:159-67. Review. No abstract available.

PMID:
9889969
32.

Dopaminergic neurons protected from degeneration by GDNF gene therapy.

Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, Davidson BL, Bohn MC.

Science. 1997 Feb 7;275(5301):838-41.

33.

Isolation of Clostridium botulinum type C from an outbreak of botulism in wild geese.

Hay CM, van der Made HN, Knoetze PC.

J S Afr Vet Med Assoc. 1973 Mar;44(1):53-6. No abstract available.

PMID:
4584656
34.

The shortage of physical therrapists. III. The use of non-physiotherapy personnel.

HAY CM.

Physiotherapy. 1961 Aug 10;47:215-8. No abstract available.

PMID:
13712430

Supplemental Content

Support Center